NIOX Group Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CSSPF research report →
Companyinvestors.niox.com
NIOX Group Plc, a diagnostics and management company, provides point-of-care fractional exhaled nitric oxide (FeNo) diagnosis and management products worldwide. Its products include NIOX VERO, a portable system for the non-invasive measurement of nitric oxide in human breath. The company was formerly known as Circassia Group Plc and changed its name to NIOX Group Plc in September 2022.
- CEO
- Jonathan Charles Emms
- IPO
- 2020
- Employees
- 91
- HQ
- Oxford, GB
Price Chart
Valuation
- Market Cap
- $336.41M
- P/E
- 37.23
- P/S
- 5.32
- P/B
- 3.54
- EV/EBITDA
- 18.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.78%
- Op Margin
- 21.97%
- Net Margin
- 14.37%
- ROE
- 10.14%
- ROIC
- 9.75%
Growth & Income
- Revenue
- $48.69M · 16.49%
- Net Income
- $7.00M · 89.16%
- EPS
- $0.02 · 92.05%
- Op Income
- $10.70M
- FCF YoY
- -3.72%
Performance & Tape
- 52W High
- $0.92
- 52W Low
- $0.69
- 50D MA
- $0.87
- 200D MA
- $0.91
- Beta
- -0.04
- Avg Volume
- 4
Get TickerSpark's AI analysis on CSSPF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CSSPF Coverage
We haven't published any research on CSSPF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CSSPF Report →